<DOC>
	<DOCNO>NCT01274663</DOCNO>
	<brief_summary>The primary purpose study evaluate safety , tolerability pharmacokinetics single oral dos PF-05175157 healthy volunteer .</brief_summary>
	<brief_title>A Study Of PF-05175157 In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Healthy male and/or female ( non childbearing potential ) subject age 18 45 year ( inclusive ) . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test . In addition , subject must normal chest xray , normal pulmonary function test normal ophthalmological examination . Body Mass Index ( BMI ) 17.5 29.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy ) . Evidence history chronic ongoing current pulmonary disease . History smoke past 5 year history evidence habitual use ( nonsmoked ) tobacco nicotinecontaining product within 3 month Screening positive cotinine test Screening Day 0 . Active ocular disease include infection , glaucoma , seasonal allergy , dryeye symptom retinal/optic nerve disease . Evidence history 'dry eyesyndrome ' , Meibomian gland disease , ocular inflammation ( eg , uveitis , iritis ) , chronic blepharitis , eye surgery include Lasik , mechanical injury chemical exposure ocular surface , use ocular lubricant , use contact lens .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Single Ascending Dose</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Safety Tolerability</keyword>
	<keyword>PK</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>